6901 — Diamond Biofund Income Statement
0.000.00%
Last trade - 00:00- TWD19.11bn
- TWD14.10bn
- -TWD2.23bn
Annual income statement for Diamond Biofund, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6,501 | 3,064 | 1,016 | -2,440 | -2,229 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 404 | 102 | 138 | 162 | 181 |
| Operating Profit | 6,097 | 2,961 | 878 | -2,602 | -2,410 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 6,091 | 2,961 | 881 | -2,584 | -2,396 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 6,090 | 2,852 | 798 | -2,583 | -2,518 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 6,090 | 2,852 | 798 | -2,583 | -2,518 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 6,090 | 2,852 | 798 | -2,583 | -2,518 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 8.13 | 3.81 | 1.03 | -3.32 | -2.96 |
| Dividends per Share |